EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Zambon completed the acquisition of Breath Therapeutics. The takeover gives Zambon control of a phase 3 treatment for a rare fatal respiratory disease. Release 

> Transgene received U.K. regulatory clearance to trial its TG6002 oncolytic virus. Statement 

> BiomX secured itself a U.S. stock listing through a deal with Chardan Healthcare Acquisition. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Nasdaq told Motif Bio that it no longer meets the minimum requirements for listing. Motif Bio has until mid-January to regain compliance. Statement 

> The AMR Centre struck a deal with Shionogi for anti-virulence program COT-143. The plan is to run clinical trials of the asset next year. Release 

> Novo Holdings’ Repair impact fund invested $10 million in Curza and Spero. Statement 

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.